
Actifuse® MIS Synthetic Bone Graft Substitute System:
- For use in open and minimally invasive procedures
- Extended reach, controlled delivery, precise placement
- Easily replaceable cartridges for additional volume requirements
Reaching new levels in synthetic bone grafting
Ideal for use in a range of spine and orthopaedic procedures:
| Posterolateral Fusion * | Interbody Fusion * |
![]() |
![]() |
| Bone Void Filling | Acetabular Cysts |
![]() |
![]() |
| Fracture Repair * | |
![]() |
* Must be used with appropriate stabilizing hardware
The Actifuse MIS cartridge contains Actifuse ABX, a unique osteostimulative bone graft:1, 2, 3:
- Accelerates bone formation
- Physiologically mediated resorption
- Demonstrated clinical success
Order information:

| Product Code |
Pack Size |
| 506005078069 | Applicator plus 1 x 7.5ml Cartridge |
| 506005078071 | Refill Cartridge 1 x 7.5ml |
Technical specifications
| Cartridge Working Length | 200mm/8inches |
| Cartridge Outside Diameter | 8mm |
| Cartridge Fill Volume | 7.5ml |
| Delivery Volume (Metered Dose) Full Squeeze Part Squeeze |
0.5ml 0.2ml |
| Key Design Features |
|
![]() |
![]() |
![]() |
![]() |
Indications for Use: Europe and Australia
The Actifuse Family of Synthetic Bone Graft Products are CE Marked in EU countries as bone graft substitutes intended to be used in place of corticocancellous, or cancellous allograft or autograft bone. The mechanical environment for such uses experience either low load requirements or compression. Typical surgical applications for bone graft substitutes are small void filling, e.g. after removal of a small bone tumour or following bone fracture reduction or in osteotomies and plastic surgery, and in spinal fusion, where a cage or screw fixation device is used to relieve the graft site form physiological loads. Bone graft substitutes are not intended to be used in place of cortical strut allograft bone where high tensile, torsion and/or bending strength are required. Bone graft substitutes are used by orthopaedic surgeons in place of allograft bone. A copy of the full Actifuse IFU for EU markets is available upon request.
References:
- Hing K. et al. Biomaterials 2006; 27: 5014-5026
- Hing K. et al. The Spine Journal 2007; 7(4): 475-490
- Wheeler D. et al. The Spine Journal 2007; 7(3): 308-317











